Covestor’s AbCellera Biologics ABCL Stock Holding History

Covestor’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-21	Closed	–	–	2039
2023 Q2	$0	Sell	21 -1	-5%	-$7	﹤0.01%	2055
2023 Q1	$0	Hold	22	–	–	﹤0.01%	1929
2022 Q4	$0	Buy	22 +4	+22%	+$46	﹤0.01%	1976
2022 Q3	$0	Buy	+18	New	+$197	﹤0.01%	1906

Other funds holding ABCL

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

FFVM

Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Covestor's ABCL Position: Q3 2023 in Review

Covestor sold out of AbCellera Biologics (ABCL) in Q3 2023, closing a stake of 21 shares.

Covestor first reported a position in ABCL in Q3 2022 and held it in 4 quarters. The position peaked at $0 in Q2 2023. 138 funds tracked by Wall St. Rank hold ABCL as of Q3 2023.

Covestor reported no remaining AbCellera Biologics position as of Q3 2023 after selling out during the quarter.
Covestor sold 21 AbCellera Biologics shares in Q3 2023.
Covestor first reported a position in AbCellera Biologics in Q3 2022 and held it in 4 quarters.
Covestor's AbCellera Biologics position peaked at $0 in Q2 2023.
138 funds tracked by Wall St. Rank held AbCellera Biologics as of Q3 2023.

Based on Covestor's 13F filing for Q3 2023, filed 13 Nov 2023.